Abdelrahman Elhusseiny, MD, MSc, sat down with David Hutton of Ophthalmology Times to discuss his presentation on the risk of posterior capsular rupture in fellow eyes of cataract surgery at this year's American Academy of Ophthalmology meeting being held in Chicago, Illinois.
The study is now expected to be fully enrolled with all 300 patients randomized by the end of 2024.
New research presented at the American Academy of Ophthalmology’s Cornea Subspecialty Day is part of the part of the 8-year Zoster Eye Disease Study.
In the first five months of the program at Henrietta Johnson Medical Center, 26% of patients with images gradable by EyeArt tested positive for either more-than-mild or vision-threatening diabetic retinopathy.
How cell phone use can affect student retention and attention in the classroom.
This initiative is supported by a $5 million grant from the Knights Templar Eye Foundation.
A home self-imaging device can provide ophthalmologists with actionable insight between office visits for AMD
According to the company, there are no FDA-approved pharmacological therapies for age-related cataracts. Its C-KAD eye drop, improves vision in patients with early-to-moderate cataracts, by penetrating the eye to reduce lens clouding, the main cause for cataracts.
PMC-403 is a novel TIE2-activating antibody with a mechanism that stabilizes pathological, leaky blood vessels.
A large study performed in Canada analyzed data and found that patients are at higher risk of multiple possible complications after cataract surgery.
Non-invasive, painless laser can reduce risk of vision loss
Thomas Aaberg, Jr, MD, Neurotech's Chief Medical Officer, shared some insights on the company's recent presentation as well as their upcoming presentations at the annual American Academy of Ophthalmology meeting being held in Chicago, Illinois.
Steven Yeh, MD, discussed his recent presentation at the Retina Society meeting and shared what he is looking forward to presenting at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.
The researchers identified 12 eyes of 7 patients (mean age, 73.3 years; 4 women) with noninfectious IOI after intravitreal faricimab injections.
The annual American Academy of Ophthalmology meeting will include notable data and announcements for many companies in the ophthalmic space as they discuss upcoming and ongoing clinical trials as well as corporate and product developments.
According to data presented this week at the 128th annual meeting of the American Academy of Ophthalmology, being held in Chicago, about three-quarters of medication volume remains in multiuse eye drop bottles tossed in the garbage well before FDA-regulated expiration dates.
Centricity Vision announced new ZEPTOLink enhancements, reducing treatment time by up to 60%. These updates, aimed at improving cataract surgery efficiency and control, will be showcased at the 2024 American Academy of Ophthalmology Annual Meeting in Chicago.
David Eichenbaum, MD and Riad Sherif, MD, CEO of Oculis will present the updates with additional info on topline results from the ACUITY Phase 2 trial of OCS-05 for the treatment of acute optic neuritis (AON).
AEYE Health will attend the American Academy of Ophthalmology (AAO) Annual Meeting, from October 18-21 in Chicago.
This patented technology is designed to enhance the light sensitivity of a multi-characteristic opsin developed by Nanoscope as a gene therapy.
The European Association for Vision and Eye Research 27th EVER Congress will be held in Valencia, Spain, November 3 – 5, 2024.
The event will focus on UNITY’s ongoing Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) head-to-head against aflibercept in DME.
Applied Science, Inc. (ASI) is expanding its AdaptivMD chronic care workflow technology
The American Academy of Ophthalmology 2024 annual meeting features key lectures and award sessions, highlighting advancements in ophthalmology from leading experts across the field.
According to the company, the platform accompanies the launch of Qdata Retinitis Pigmentosa for life sciences and the development of Practice Insights for clinicians.
According to the company, MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration in advanced retinitis pigmentosa (RP), irrespective of gene mutation.
The Eye Care Network adds a longstanding, CME-certified conference to its live event programming
American Academy of Ophthalmology offers in-person and virtual options for annual meeting, Subspecialty Day.
